Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBS-101
- Development stage
- Preclinical
- Lead developer
- CiRC Biosciences
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
CBS-101 is an investigational allogeneic cell replacement therapy being developed by CiRC Biosciences for the treatment of Retinitis Pigmentosa (RP). The therapy is based on a proprietary chemically induced reprogramming (CiRC) platform that enables the direct conversion of fibroblasts into functional retinal cells, specifically photoreceptors, using a cocktail of small molecules rather than viral vectors or genetic modification. By replacing damaged or lost photoreceptor cells in the retina, CBS-101 aims to restore visual function in patients suffering from RP, a progressive degenerative eye disease. The approach is designed to be an 'off-the-shelf' allogeneic product, potentially offering a scalable solution for retinal regeneration.
Beyond the preview
Go deeper on CBS-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBS-101.